文献速递血栓与止血

临终癌症患者抗血栓治疗的使用与心血管结局及出血风险:丹麦全国队列研究

Use of antithrombotic therapy and the risk of cardiovascular outcomes and bleeding in cancer patients at the end of life: a Danish nationwide cohort study.
PubMed 文献 · J Thromb Haemost · 2024-10-10

该丹麦全国队列纳入2013至2022年86 732例临终癌症患者,37.5%在临终宣告时正接受抗血栓治疗。抗血栓治疗平均处方覆盖天数比例为88%,1年停药发生率为7.9%,多数患者持续用药至死亡;接受抗血栓治疗者1年静脉血栓栓塞风险较低,但动脉血栓栓塞和大出血风险较高。

要点

  • 临终宣告时37.5%患者正接受抗血栓治疗,其中血小板抑制剂占66.6%。
  • 抗血栓治疗平均处方覆盖天数比例为88%,1年停药发生率为7.9%。
  • 多数患者持续抗血栓治疗至死亡,血小板抑制剂使用者为74.8%。

核心结论

  • 尽管临终阶段获益-风险特征不确定,多数临终癌症患者仍持续抗血栓治疗至生命终点。
  • 接受抗血栓治疗的患者1年静脉血栓栓塞风险较低,但动脉血栓栓塞和大出血风险较高。

研究设计与样本

  • 丹麦全国队列研究,纳入2013至2022年86 732例临终癌症患者,中位年龄75岁,女性占47%,中位生存期57天。
  • 以处方覆盖天数比例(PDC)衡量临终宣告后一年内抗血栓治疗依从性,停药定义为两次处方续配之间治疗间隙≥30天。
  • 采用竞争风险模型(考虑死亡竞争风险)计算出血并发症、静脉血栓栓塞和动脉血栓栓塞的1年累积发生率。

主要发现

  • 临终宣告时37.5%患者正接受抗血栓治疗,其中血小板抑制剂占66.6%,直接口服抗凝药占23.0%,维生素K拮抗剂(VKA)占10.4%。
  • 抗血栓治疗平均PDC为88%(标准差30%),血小板抑制剂使用者最高(平均PDC 89%),VKA使用者最低(73%)。
  • 1年抗血栓治疗停药发生率为7.9%(95%CI 7.7%-8.1%)。
  • 持续抗血栓治疗至死亡的患者比例:血小板抑制剂74.8%,直接口服抗凝药58.8%,VKA 61.6%。
  • 接受抗血栓治疗的患者1年静脉血栓栓塞风险较低,但动脉血栓栓塞和大出血风险较高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite uncertain benefit-risk profile near the end of life, antithrombotic therapy (ATT) is prevalent in patients with terminal cancer. OBJECTIVES: To examine adherence and persistence with ATT in terminally ill cancer patients and investigate risks of major and clinically relevant bleeding, venous thromboembolism (VTE), and arterial thromboembolism (ATE) by ATT exposure. METHODS: Using a Danish nationwide cohort of terminal cancer patients, ATT adherence in the year following terminal illness declaration was measured by the proportion of days covered (PDC) by prescription. Discontinuation was defined as a treatment gap of ≥30 days between prescription renewals. One-year cumulative incidences of bleeding complications, VTE, and ATE were calculated, considering the competing risk of death. RESULTS: During 2013-2022, 86 732 terminally ill cancer patients were identified (median age, 75 years; 47% female; median survival, 57 days). At terminal illness declaration, 37.5% were receiving ATT (66.6% platelet inhibitors, 23.0% direct oral anticoagulants, and 10.4% vitamin K antagonists [VKAs]). The mean PDC with ATT was 88% (SD, 30%), highest among platelet inhibitor users (mean PDC, 89%) and lowest among VKA users (73%). One-year ATT discontinuation incidence was 7.9% (95% CI, 7.7%-8.1%). Most patients continued ATT until death (74.8% platelet inhibitors, 58.8% direct oral anticoagulants, and 61.6% VKAs). Patients receiving ATT had a lower 1-year VTE risk but higher risks of ATE and major bleeding. CONCLUSION: Despite uncertain benefit-risk profile, most terminally ill cancer patients continue ATT until the end of life. These findings provide insights into current ATT utilization and discontinuation dynamics in the challenging context of terminal illness.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Søgaard M, Ørskov M, Jensen M, et al. Use of antithrombotic therapy and the risk of cardiovascular outcomes and bleeding in cancer patients at the end of life: a Danish nationwide cohort study. J Thromb Haemost. 2024. PMID: 39393778. doi:10.1016/j.jtha.2024.09.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。